{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:14:24Z","timestamp":1760955264075},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00270-010-0086-6","type":"journal-article","created":{"date-parts":[[2011,1,3]],"date-time":"2011-01-03T14:40:48Z","timestamp":1294065648000},"page":"82-89","source":"Crossref","is-referenced-by-count":19,"title":["Transarterial Chemoembolization With Cisplatin as Second-Line Treatment for Hepatocellular Carcinoma Unresponsive to Chemoembolization With Epirubicin-Lipiodol Emulsion"],"prefix":"10.1007","volume":"35","author":[{"given":"Noboru","family":"Maeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"issue":"5 Suppl 1","key":"86_CR1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5\u2013S16","journal-title":"Gastroenterology"},{"issue":"2","key":"86_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429\u2013442","journal-title":"Hepatology"},{"issue":"9319","key":"86_CR3","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734\u20131739","journal-title":"Lancet"},{"issue":"1","key":"86_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","volume":"224","author":"C Camm\u00e0","year":"2002","unstructured":"Camm\u00e0 C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1):47\u201354","journal-title":"Radiology"},{"key":"86_CR5","doi-asserted-by":"crossref","unstructured":"Brown DB, Cardella JF, Sacks D et al (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20(7 Suppl):S219\u2013S226, S226.e1\u201310","DOI":"10.1016\/j.jvir.2009.04.033"},{"issue":"4","key":"86_CR6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1872-034X.2008.00466.x","volume":"39","author":"Y Kawamura","year":"2009","unstructured":"Kawamura Y, Ikeda K, Hirakawa M et al (2009) Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 39(4):346\u2013354","journal-title":"Hepatol Res"},{"issue":"3","key":"86_CR7","first-page":"252","volume":"24","author":"A Seki","year":"2009","unstructured":"Seki A, Igarashi T, Kawauchi T et al (2009) Transcatheter arterial chemoembolization with cisplatin-Lipiodol emulsion for epirubicin-Lipiodol TACE resistant unresectable hepatocellular carcinoma: Initial evaluation of efficacy and toxicity [in Japanese]. Jpn J Intervent Radiol 24(3):252\u2013257","journal-title":"Jpn J Intervent Radiol"},{"issue":"5","key":"86_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","volume":"38","author":"M Yoshikawa","year":"2008","unstructured":"Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38(5):474\u2013483","journal-title":"Hepatol Res"},{"issue":"6","key":"86_CR9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jvir.2010.02.009","volume":"21","author":"N Maeda","year":"2010","unstructured":"Maeda N, Osuga K, Higashihara H et al (2010) In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization. J Vasc Interv Radiol 21(6):877\u2013881","journal-title":"J Vasc Interv Radiol"},{"issue":"81","key":"86_CR10","first-page":"202","volume":"55","author":"Y Takaki","year":"2008","unstructured":"Takaki Y, Kaminou T, Shabana M et al (2008) Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature. Hepatogastroenterology 55(81):202\u2013206","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"86_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"86_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):21\u201330","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"86_CR13","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S0168-8278(02)00432-4","volume":"38","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38(Suppl 1):S136\u2013S149","journal-title":"J Hepatol"},{"issue":"13","key":"86_CR14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas D, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(13):176\u2013781","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"86_CR15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171","journal-title":"Hepatology"},{"issue":"4","key":"86_CR16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/bjc.1995.134","volume":"71","author":"DW Shen","year":"1995","unstructured":"Shen DW, Akiyama S, Schoenlein P et al (1995) Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 71(4):676\u2013683","journal-title":"Br J Cancer"},{"key":"86_CR17","doi-asserted-by":"crossref","unstructured":"Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23(6):564\u2013548","DOI":"10.1097\/00000421-200012000-00006"},{"issue":"4","key":"86_CR18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00270-009-9570-2","volume":"32","author":"T Kawaoka","year":"2009","unstructured":"Kawaoka T, Aikata H, Takaki S et al (2009) Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 32(4):687\u2013694","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"86_CR19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00270-008-9367-8","volume":"31","author":"K Morimoto","year":"2008","unstructured":"Morimoto K, Sakaguchi H, Tanaka T et al (2008) Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer. Cardiovasc Intervent Radiol 31(5):981\u2013985","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"86_CR20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00270-008-9379-4","volume":"31","author":"K Lu","year":"2008","unstructured":"Lu K, Li YH, He XF et al (2008) Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol 31(6):1133\u20131140","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-010-0086-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-010-0086-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-010-0086-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T10:06:18Z","timestamp":1559901978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-010-0086-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["86"],"URL":"https:\/\/doi.org\/10.1007\/s00270-010-0086-6","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,4]]}}}